Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000129511 | SCV000184285 | likely benign | Hereditary cancer-predisposing syndrome | 2015-11-13 | criteria provided, single submitter | clinical testing | Insufficient or conflicting evidence |
Labcorp Genetics |
RCV000467516 | SCV000542149 | benign | Neurofibromatosis, type 1 | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001582594 | SCV001812837 | uncertain significance | not provided | 2021-11-02 | criteria provided, single submitter | clinical testing | Observed in individuals with sarcoma (Ballinger 2016); Reported in healthy controls, but not in any cases from a breast cancer study (Momozawa 2018); In silico analysis supports that this missense variant does not alter protein structure/function; Also known as p.Val2839Met; This variant is associated with the following publications: (PMID: 24728327, 23656349, 30287823, 27498913) |
Sema4, |
RCV000129511 | SCV002528157 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-06-03 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002444579 | SCV002678408 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2020-06-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
St. |
RCV000467516 | SCV004031237 | uncertain significance | Neurofibromatosis, type 1 | 2023-07-25 | criteria provided, single submitter | clinical testing | The NF1 c.8452G>A (p.Val2818Met) missense change has a maximum subpopulation frequency of 0.0065% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. This variant has been reported in a large case-control study of breast cancer in 8 of 60,466 cases and 9 of 53,461 controls (PMID: 33471991). To our knowledge, this variant has not been reported in individuals with Neurofibromatosis type 1. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
ITMI | RCV000121641 | SCV000085839 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |